

Bao-Hui Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4287113/publications.pdf>

Version: 2024-02-01

142
papers

11,971
citations

147566

31
h-index

28224

105
g-index

149
all docs

149
docs citations

149
times ranked

11249
citing authors

#	ARTICLE	IF	CITATIONS
1	Gefitinib or Carboplatin+Paclitaxel in Pulmonary Adenocarcinoma. <i>New England Journal of Medicine</i> , 2009, 361, 947-957.	13.9	7,606
2	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1569.	3.4	388
3	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2197-2204.	0.8	323
4	Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. <i>Lancet Oncology</i> , 2012, 13, 466-475.	5.1	236
5	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology) <i>Tj ETQq1 1 0.784314288 /Over</i>	0.784314288	128
6	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018, 118, 654-661.	2.9	192
7	ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1682-1689.	0.5	151
8	Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 643-652.	0.5	123
9	Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth. <i>Clinical Cancer Research</i> , 2007, 13, 5455-5462.	3.2	120
10	Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 663-672.	0.5	100
11	EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. <i>Lung Cancer</i> , 2017, 113, 37-44.	0.9	99
12	Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. <i>International Journal of Cancer</i> , 2017, 141, 1249-1256.	2.3	96
13	EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. <i>Lung Cancer</i> , 2016, 96, 87-92.	0.9	81
14	Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. <i>Oncologist</i> , 2019, 24, 157-e64.	1.9	79
15	Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Diagnosing Intrathoracic Tuberculosis. <i>Annals of Thoracic Surgery</i> , 2013, 96, 2021-2027.	0.7	78
16	Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening. <i>Lung Cancer</i> , 2018, 117, 20-26.	0.9	78
17	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1104-1109.	0.5	75
18	Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. <i>European Journal of Cancer</i> , 2013, 49, 3111-3121.	1.3	70

#	ARTICLE	IF	CITATIONS
19	Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1227-1235.e2.	0.4	62
20	Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. <i>European Respiratory Journal</i> , 2019, 53, 1801562.	3.1	61
21	Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma. <i>Journal of Thoracic Disease</i> , 2016, 8, 2610-2616.	0.6	53
22	Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 347-353.	0.5	50
23	Mitofusin-2 over-expresses and leads to dysregulation of cell cycle and cell invasion in lung adenocarcinoma. <i>Medical Oncology</i> , 2015, 32, 132.	1.2	45
24	Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. <i>Lung Cancer</i> , 2017, 104, 119-125.	0.9	41
25	Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies. <i>International Journal of Cancer</i> , 2020, 146, 3124-3133.	2.3	40
26	Endobronchial Ultrasound Elastography for Evaluation of Intrathoracic Lymph Nodes: A Pilot Study. <i>Respiration</i> , 2017, 93, 327-338.	1.2	39
27	Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2031-2040.	1.2	36
28	The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303). <i>Oncologist</i> , 2020, 25, e870-e874.	1.9	36
29	High-resolution Computed Tomography Features Distinguishing Benign and Malignant Lesions Manifesting as Persistent Solitary Subsolid Nodules. <i>Clinical Lung Cancer</i> , 2018, 19, e75-e83.	1.1	35
30	Placental Growth Factor Promotes Metastases of Non-Small Cell Lung Cancer Through MMP9. <i>Cellular Physiology and Biochemistry</i> , 2015, 37, 1210-1218.	1.1	34
31	Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small cell lung cancer patients with EGFR mutations. <i>International Journal of Cancer</i> , 2017, 140, 1645-1652.	2.3	34
32	Effect of Polymorphisms in XPD on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2012, 7, e33200.	1.1	32
33	Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer. <i>Gene</i> , 2016, 591, 58-64.	1.0	32
34	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 32-37.	0.9	32
35	Determining Factors in Diagnosing Pulmonary Sarcoidosis by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. <i>Annals of Thoracic Surgery</i> , 2015, 99, 441-445.	0.7	31
36	Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer. <i>Advanced Science</i> , 2019, 6, 1900721.	5.6	30

#	ARTICLE	IF	CITATIONS
37	A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab. <i>Oncolmmunology</i> , 2020, 9, 1731072.	2.1	30
38	Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment. <i>Cancer Biology and Medicine</i> , 2018, 15, 443.	1.4	29
39	hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527. <i>Cell Death and Disease</i> , 2021, 12, 807.	2.7	29
40	Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells. <i>BMC Medical Genomics</i> , 2019, 12, 38.	0.7	28
41	Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. <i>Journal of International Medical Research</i> , 2020, 48, 030006051988727.	0.4	27
42	Different characteristics and survival in nonâ€small cell lung cancer patients with primary and acquired EGFR T790M mutation. <i>International Journal of Cancer</i> , 2019, 144, 2880-2886.	2.3	25
43	A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. <i>Scientific Reports</i> , 2014, 4, 4813.	1.6	23
44	Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma. <i>Tumor Biology</i> , 2014, 35, 4921-4928.	0.8	22
45	A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Nonâ€Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 27-34.	1.1	21
46	Adjuvant chemotherapy may improve prognosis after resection of stage I lung cancer with lymphovascular invasion. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 2006-2015.e2.	0.4	21
47	Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1325-1330.	1.2	20
48	Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer. <i>Lung Cancer</i> , 2018, 125, 245-252.	0.9	20
49	Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line. <i>Frontiers in Oncology</i> , 2019, 9, 886.	1.3	20
50	Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 7050-7058.	0.8	19
51	Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas. <i>Cancer</i> , 2018, 124, 2399-2406.	2.0	19
52	Predictors of recurrence and survival of pathological T1N0M0 invasive adenocarcinoma following lobectomy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1015-1023.	1.2	19
53	Effect of anlotinib as a thirdâ€or furtherâ€line therapy in advanced nonâ€small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial. <i>Cancer Medicine</i> , 2020, 9, 2621-2630.	1.3	19
54	Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1357-1365.	2.8	19

#	ARTICLE	IF	CITATIONS
55	Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880180.	0.8	18
56	Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 401-406.	1.2	18
57	Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. <i>Cancer Biology and Medicine</i> , 2021, 18, 816-824.	1.4	18
58	Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. <i>Targeted Oncology</i> , 2019, 14, 169-178.	1.7	17
59	Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2261-2274.	2.0	17
60	Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Endostatin and Paclitaxel-Carboplatin Chemotherapy? A Retrospective Study. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1781-1789.	0.5	15
61	Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 373-380.	2.8	15
62	Primary thoracic extraskeletal osteosarcoma: a case report and literature review. <i>Journal of Thoracic Disease</i> , 2017, 9, E1088-E1095.	0.6	15
63	ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors. <i>BMC Medicine</i> , 2022, 20, 170.	2.3	15
64	Effects of para-toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial. <i>Lung Cancer</i> , 2016, 98, 43-50.	0.9	14
65	Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , 2017, 18, S3.	5.1	14
66	Advanced Non-Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy. <i>Journal of Immunotherapy</i> , 2020, 43, 189-195.	1.2	14
67	Role of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of bronchogenic carcinoma: Experience of a single institution in China. <i>Thoracic Cancer</i> , 2010, 1, 28-34.	0.8	13
68	XPA gene rs1800975 single nucleotide polymorphism and lung cancer risk: a meta-analysis. <i>Tumor Biology</i> , 2014, 35, 6607-6617.	0.8	13
69	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 309-314.	1.1	13
70	Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)? <i>Lung Cancer</i> , 2018, 117, 27-31.	0.9	13
71	Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients. <i>Lung Cancer</i> , 2019, 135, 138-144.	0.9	13
72	Development and validation of a predictive model for the diagnosis of solid solitary pulmonary nodules using data mining methods. <i>Journal of Thoracic Disease</i> , 2019, 11, 950-958.	0.6	13

#	ARTICLE	IF	CITATIONS
73	Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery. <i>Lung Cancer</i> , 2020, 141, 72-77.	0.9	13
74	Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study. <i>Targeted Oncology</i> , 2020, 15, 175-184.	1.7	13
75	CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1049.	1.3	13
76	Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis. <i>Cell Death and Disease</i> , 2021, 12, 170.	2.7	13
77	DUBR suppresses migration and invasion of human lung adenocarcinoma cells via ZBTB11-mediated inhibition of oxidative phosphorylation. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 157-166.	2.8	13
78	Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 2392-2400.	0.7	12
79	Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 556194.	1.3	12
80	MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 83051-83059.	0.8	12
81	OCT4&SOX2-specific cytotoxic T lymphocytes plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem-like cells in vitro and treating drug-resistant lung cancer mice in vivo. <i>Journal of Cellular Physiology</i> , 2019, 234, 6758-6768.	2.0	11
82	Polymeric micellar paclitaxel (Pm-Pac) prolonged overall survival for NSCLC patients without pleural metastasis. <i>International Journal of Pharmaceutics</i> , 2022, 623, 121961.	2.6	11
83	Transcriptional profiling revealed the anti-proliferative effect of MFN2 deficiency and identified risk factors in lung adenocarcinoma. <i>Tumor Biology</i> , 2016, 37, 8643-8655.	0.8	10
84	Predicting the recurrence risk factors and clinical outcomes of peripheral pulmonary adenocarcinoma with wedge resection. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1043-1051.	1.2	10
85	Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 773-779.	1.6	10
86	Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study. <i>Lung Cancer</i> , 2019, 130, 18-24.	0.9	10
87	TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 732125.	2.2	10
88	Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 582-589.	2.3	10
89	<p>The Association Between RAPS N Methylation in Peripheral Blood and Early Stage Lung Cancer Detected in Case&Control Cohort<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11063-11075.	0.9	9
90	Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring <i>STK11</i> or <i>KEAP1</i> mutation. <i>Oncolmmunology</i> , 2021, 10, 1865670.	2.1	9

#	ARTICLE	IF	CITATIONS
91	ctDNA-Profilng-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients. <i>Frontiers in Genetics</i> , 2021, 12, 723670.	1.1	9
92	Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 708558.	2.2	9
93	mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
94	NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis. <i>Tumor Biology</i> , 2013, 34, 3967-3979.	0.8	8
95	Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 652560.	1.3	8
96	RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 1490-1498.	2.8	7
97	Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment. <i>Clinical Lung Cancer</i> , 2019, 20, e631-e637.	1.1	7
98	Does surgically resected small-cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?. <i>Thoracic Cancer</i> , 2020, 11, 1239-1244.	0.8	7
99	Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer. <i>Annals of Palliative Medicine</i> , 2020, 9, 1681-1687.	0.5	7
100	Clinical significance of visceral pleural and lymphovascular invasion in surgically resected adenosquamous lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 59, 617-623.	0.6	7
101	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	1.3	7
102	First 30 endobronchial ultrasound-guided transbronchial needle aspirations: a single institution's early experience. <i>Chinese Medical Journal</i> , 2011, 124, 1818-23.	0.9	7
103	Adjuvant Chemotherapy Improves Survival in Surgically Resected Stage IB Squamous Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1683-1689.	0.7	6
104	Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China. <i>Clinical Lung Cancer</i> , 2020, 21, e355-e362.	1.1	6
105	Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 665484.	1.3	6
106	Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study. <i>Chinese Clinical Oncology</i> , 2016, 5, 79-79.	0.4	6
107	The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma. <i>Cancer Medicine</i> , 2022, 11, 1299-1309.	1.3	6
108	Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study. <i>Thoracic Cancer</i> , 2022, , .	0.8	6

#	ARTICLE	IF	CITATIONS
109	Lung cancer and benign lung diseases in patients with serious vitamin D deficiency in eastern China. <i>Thoracic Cancer</i> , 2012, 3, 303-306.	0.8	5
110	Utility of endobronchial ultrasoundâ€guided transbronchial needle aspiration in diagnosing nonâ€specific inflammatory intrathoracic lymphadenitis. <i>Clinical Respiratory Journal</i> , 2018, 12, 691-698.	0.6	5
111	FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor. <i>Life Sciences</i> , 2021, 268, 119022.	2.0	5
112	Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. <i>Respiratory Research</i> , 2021, 22, 145.	1.4	5
113	Occurrence of hypertension during thirdâ€line anlotinib is associated with progressionâ€free survival in patients with squamous cell lung cancer (<sc>SCC</sc>): A post hoc analysis of the <sc>ALTER0303</sc> trial. <i>Thoracic Cancer</i> , 2021, 12, 2345-2351.	0.8	5
114	Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations. <i>Frontiers in Oncology</i> , 2021, 11, 681429.	1.3	5
115	Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. <i>International Immunopharmacology</i> , 2021, 98, 107734.	1.7	5
116	Novel blood-based hypomethylation of SH3BP5 is associated with very early-stage lung adenocarcinoma. <i>Genes and Genomics</i> , 2022, 44, 445-453.	0.5	5
117	Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 28-39.	0.7	5
118	Establishment and management of a lung cancer biobank in Eastern <sc>C</sc>hina. <i>Thoracic Cancer</i> , 2015, 6, 58-63.	0.8	4
119	Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2020, 2020, 1-7.	0.6	4
120	Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis. <i>Targeted Oncology</i> , 2020, 15, 337-345.	1.7	4
121	EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study. <i>Clinical Lung Cancer</i> , 2021, 22, e395-e404.	1.1	4
122	The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma. <i>Cancer Letters</i> , 2022, 532, 215599.	3.2	4
123	Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1417-1424.	1.2	4
124	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174.	2.0	3
125	Epidermal Growth Factor Receptor (EGFR)â€Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma. <i>Targeted Oncology</i> , 2019, 14, 423-431.	1.7	3
126	Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases. <i>Journal of Cardiothoracic Surgery</i> , 2019, 14, 63.	0.4	3

#	ARTICLE	IF	CITATIONS
127	Tumour mutational burden in treatment-resistant tumours. <i>Lancet Oncology</i> , The, 2020, 21, e551.	5.1	3
128	PIGF knockdown attenuates hypoxia-induced stimulation of cell proliferation and glycolysis of lung adenocarcinoma through inhibiting Wnt/ β^2 -catenin pathway. <i>Cancer Cell International</i> , 2021, 21, 18.	1.8	3
129	Association between polymorphisms of autophagy pathway and responses in non-small cell lung cancer patients treated with platinum-based chemotherapy. <i>Yi Chuan = Hereditas / Zhongguo Yi Chuan Xue Hui Bian Ji</i> , 2017, 39, 250-262.	0.1	3
130	Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 5666-5678.	0.7	3
131	Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review. <i>Targeted Oncology</i> , 2018, 13, 631-639.	1.7	2
132	Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery. <i>Lung Cancer</i> , 2021, 154, 124-130.	0.9	2
133	Clinical analysis of Gefitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations. <i>Thoracic Cancer</i> , 2013, 4, 433-439.	0.8	1
134	Serum TNFR1: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 4150-4156.	1.6	1
135	Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study). <i>BMC Cancer</i> , 2022, 22, 294.	1.1	1
136	Utility and Safety of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Diagnosis of Isolated Mediastinal Masses. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 2047-2052.	1.1	0
137	Interstitial lung abnormalities: What do we know and how do we manage?. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1551-1561.	1.0	0
138	Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2022, 13, 812555.	1.6	0
139	Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia Signals. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 840466.	1.8	0
140	<i>FYB</i> methylation in peripheral blood as a potential marker for the early-stage lung cancer: a case-control study in Chinese population. <i>Biomarkers</i> , 2022, 27, 79-85.	0.9	0
141	ASO Visual Abstract: Different Characteristics and Survival Between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
142	ASO Author Reflections: Pure and Combined Surgically Resected Large Cell Neuroendocrine Carcinoma of Lung: Could They be Evaluated as a Single Entity?. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0